Acumen plans presentation of Phase 2 sabirnetug trial baseline data at CTAD
Bitget2026/10/22 11:31- Acumen Pharmaceuticals will present three posters on its Phase 2 ALTITUDE-AD trial of sabirnetug for early Alzheimer’s disease.
- Presentations are scheduled for Nov. 16-17, 2026, at the Clinical Trials on Alzheimer’s Disease conference in Boston, running Nov. 16-19.
- The posters will cover preliminary participant baseline characteristics, treatment expectations and motivations, and care partners’ experiences.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bitcoin closed above the 50-week moving average on Thursday.
Morgan Stanley comments on Coherent (COHR.US) Q1 financial report: not perfect but "good enough", the real highlight is the 20 billions USD long-term contract
Morgan Stanley has released its commentary on Coherent (COHR.US) following the company’s fiscal Q1 2027 earnings report, maintaining an "Equal-weight" rating and a target price of $325.
Nasdaq’s Staking Move: This Altcoin ETF News Stands Out from the Market! Here Are the Details
AI transformation potential does not equal investment returns! Plato Asset Management says the market is confusing two major logics, Nasdaq's plunge is just a "reality test"
David Allen, Head of Long/Short Strategies at Plato Investment Management, stated in an interview that Thursday's US stock market sell-off was the result of investors conflating the transformative potential of artificial intelligence (AI) with the actual investment return argument.
Crypto prices
More
